EMA Recommends Extending Indications for Pembrolizumab and Adopted a New Pharmaceutical Form Along with a New Route of Administration By Ogkologos - October 3, 2025 260 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns treatment of patients with resectable locally advanced head and neck squamous cell carcinoma Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated... August 14, 2025 Scientists find cells in centre of tumours are most likely to... May 18, 2021 Improving Care for Underserved People With Cancer and Evaluating Delays in... September 20, 2021 Osimertinib Improves Survival in Advanced Lung Cancer with EGFR Mutations December 12, 2019 Load more HOT NEWS ASCO Annual Meeting 2023: Radiation Therapy May Not Be Needed After... New Drug Regimen Cures More Children with Aggressive B-Cell Lymphoma Brentuximab Approved for Initial Treatment of Advanced Hodgkin Lymphoma Working Mom with Stage II Breast Cancer Receives Custom Wig Made...
